Kurt Soost, CFA’s Post

Who says you can't buy much for $1 anymore? One common share of ImmunoPrecise Antibodies(NASDAQ: IPA $0.995) can be purchased for less than $1 USD. "I'm a great believer in luck, and I find the harder I work, the more I have of it." - Thomas Jefferson I am hopeful that some smart, hard-working stock market participants/analysts will take my hint and spend some time completing some due diligence/research on ImmunoPrecise... Hard to believe after much research and analysis that this is trading at an approximate market capitalization of $27 million. IPA (ImmunoPrecise Antibodies) BioStrand (a subsidiary of IPA) InterSystems #LENSai #Biotech #ai #HYFTs #HYFTTechnology #drugdiscovery #healthcare #pharma #personalizedmedicine #omics #AIDrugDiscovery #systemthinking #bioinformatics #antibodies #machinelearning #multiomics #LLMs #datascience #computationalbiology #nlp #ontologies #semantics #knowledgegraphs #lifesciences #bigdata #informationintegrationdilemma #patternrecognition #insilico #molecularbiologists #aminoacids #dna #rna #HYFTpatterns https://lnkd.in/gJnNzMjJ

ImmunoPrecise Antibodies Ltd.(NASDAQ: IPA $1.01) Investors, Healthcare/Pharmaceutical Researchers & Executives, and Artificial Intelligence(AI) Advocates really need to read this Investor Report - "Unleashing The Potential"(attached below) Please read in the context of all the recent news/developments at ImmunoPrecise Antibodies. Especially regarding their new partnership with InterSystems(the leading provider of data solutions for industries with complex challenges like healthcare...) IPA (ImmunoPrecise Antibodies) BioStrand (a subsidiary of IPA) InterSystems Dirk Van Hyfte Ingrid Brands Arnout Van Hyfte #ai #HYFTs #HYFTTechnology #drugdiscovery #healthcare #biotech #pharma #personalizedmedicine #omics #LENSai #immunoprecise #AIDrugDiscovery #systemthinking #bioinformatics #antibodies #machinelearning #multiomics #multimodality #biotherapeutics #techbio #LLMs #datascience #nlp #ontologies #semantics #knowledgegraphs #lifesciences #bigdata #informationintegrationdilemma #patternrecognition #insilico https://lnkd.in/g9rQmrvk

Brilliant work Dr. Van Hyfte & Team!!!!

Fascinating Low Valuation on IPA Therapeutics(NASDAQ:IPA $1.29) On March 29, 2022 IPA paid $20 million pounds or approximately $26.4 million USD for BioStrand AI. The pound was trading(1 pound = 1.32 USD) at this time. Since this acquisition BioStrand AI has announced several significant events/successes including, granting of the HYFT Technology Patent by the European Patent Office(EPO), BioStrand solves the Information Integration Dilemma(IID), BioStrand creates a revolutionary approach to biological sequence retrieval, BioStrand introduces an advanced Foundational AI Model utilizing LLM stacking & HYFT Technology, InterSystems & BioStrand AI Collaborate to Unveil Innovative Integration of Vector Search, BioStrand's AI has been learning from IPA's leading, proprietary Anti-Body Discovery Database(possibly the best in the World)for the last 24 months, and much more. IPA has been working on antibody research for 40+ years. https://lnkd.in/gJHWdgck https://blog.biostrand.ai Yet, the entire current Market Capitalization of IPA(CRO + BioStrand + Talem) is approximately $35 million USD today. IPA's Contract Research Organization(CRO) has had 3 record revenue quarters in a row, is growing at approx. 20%, and Fiscal 2024 Revenue should be around $20 million USD. They deal with 19 of the top 20 pharmas, and have over 600 partners. One could argue that the CRO is worth between $80-$120 million. FairJourney Biologics(an excellent CRO) was just put up for sale for $1 Billion+. Although FJBio has $45 million in EBITA, IPA has better numbers regarding projects, libraries generated, partners, species used, and 1/2 the employees. In other words, better data to train the AI models. Wet lab combined with AI will be critical moving forward. I also believe BioStrand AI is undiscovered by most stock market participants. For Information Purposes Only. Please complete your own due diligence. CFP has a position in IPA. Is a short squeeze possible? Sum of the parts(1 + 1 = 11) IPA (ImmunoPrecise Antibodies)BioStrand (a subsidiary of IPA) InterSystems #ai #HYFTTechnology #drugdiscovery #LENSai #antibodies #LLMS #NLP #semantics #pharma #healthcare #biotech #multimodality

Fascinating "Use Case" showcasing the incredible power/potential of LENSai powered by HYFT Technology in Life Sciences. Healthcare/Pharmaceutical/Biotech Companies will soon be able to "optimize the value of their data" at a sub-sequence level. This is the "Holy Grail" in omics data analysis and insights. All these companies need to do is contact BioStrand. HYFTs are Universal Fingerprints patterns found across the entire biosphere. A heavily patented discovery by Dr. Dirk van Hyfte. The HYFTs significantly reduce the noise to make data meaningful. HYFTs allow for 1000X more efficient processing of data. LENSai takes a "White Box" AI approach. Concepts and relations are traceable. All information that is displayed can be traced back to the original source it came from. No "Black Box" not sure where the answer came from AI approach here!! I am unaware of any other company that has these capabilities on Earth. Please let me know if you are aware of any other? Congratulations BioStrand Team!!! All this, yet the intelligent investment community is giving BioStrand very little value, as a fully-owned subsidiary of ImmunoPrecise (NASDAQ: IPA $1.47). I will make a bold prediction that this will change soon!!! What are you waiting for?